The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC).
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Luc Cabel
No Relationships to Disclose
 
Jimmitti Teysir
No Relationships to Disclose
 
Julia An
No Relationships to Disclose
 
Samuel Rivero-Hinojosa
Employment - Natera
Travel, Accommodations, Expenses - Natera
 
Sandro Satta
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Sara Bristow
Employment - InVitae; Natera
Stock and Other Ownership Interests - Natera
 
Ekaterina Kalashnikova
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Angel Rodriguez
Employment - Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
 
Minetta Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Mark Robson
Consulting or Advisory Role - OptumHealth
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Foundation Medicine; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Casdin Capital; Daiichi Sankyo; Hexagon; Lilly; Novartis; Prelude Therapeutics; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo